Progress in the treatment of diffuse large B-cell lymphomas: a German perspective

Published: June 8, 2009
Abstract Views: 165
PDF: 243
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Young good-prognosis patients comprise the low and low-intermediate risk group (risk factor 0 and 1 according to the age-adjusted IPI) while poor-prognosis patients comprise the high-intermediate and high risk group (≥2 risk factors). Optimum treatment responses in young good-prognosis patients have so far been achieved with 6 cycles of a CHOP-like chemotherapy in combination with the anti-CD20 antibody rituximab. Using this therapeutic approach, 3-year event-free survival rates of >90% and overall survival of >97% can be achieved in a very favorable subgroup (patients without IPI risk factor and no bulky disease), while further improvement is warranted for the less favorable subgroup (IPI=I and/or bulky disease; 3-year event-free survival: 77%).

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Pfreundschuh, M. (2009). Progress in the treatment of diffuse large B-cell lymphomas: a German perspective. Hematology Meeting Reports (formerly Haematologica Reports), 2(7). https://doi.org/10.4081/hmr.v2i7.420